Could a single pill crack the code of treating Alzheimer's disease?
By targeting toxic protein clumps in the brain, Dr. Martin Tolar, founder-CEO of Alzheon, aims to outsmart Alzheimer’s decades ahead of symptoms - and reshape global neurology.
enGene injects new hope into the future of bladder cancer care
Ron Cooper, ex-Albireo CEO, is betting on enGene’s novel gene delivery platform to sidestep BCG shortfalls and transform bladder cancer treatment worldwide.
Is a world without eyedrops possible?
SpyGlass Pharma is poised to revolutionize glaucoma treatment by implanting an innovative long-term drug delivery system directly inside the eye. Their treatment promises to continuously release eyedrop medication for 3 years after surgery, as opposed to using eye drops manually every day.
GERD affects millions of Americans. This drug is the first major innovation in three decades.
GERD affects 65 million Americans, yet innovation in treatment had stagnated. Phathom Pharmaceuticals' FDA approval of VOQUEZNA® (vonoprazan) is a big moment for patients.
Let there Belite: the prospect of an oral pill for vision loss
If left untreated, Stargardt disease and Geographic Atrophy almost always lead to vision loss and blindness - but a groundbreaking oral treatment in the last stage of clinical trials offers new hope.
How ImmunityBio is transforming cancer - a treatment in just 30 seconds
“I think I'm blessed with truly the best team in all of pharma… we are doing something that's bigger than all of us!”
Ocugen has a cure in sight... will it get FDA approval soon?
“The cost of gene therapies can reach millions of dollars per patient… Our goal is developing cost-effective treatments that can be accessible globally.”
Gene therapy in ophthalmology is on the cusp of a breakthrough
"One of our first patients was treated over five years ago. He had received 109 injections over 10 years, and five years after a single Ixo-Vec injection, he is free of injections with stable vision and no fluid in the eye."
CAR T-cell therapies beat blood cancer - can they do the same for autoimmune diseases?
CAR T-cell therapies are often lauded as one of the industry’s most important frontiers, and these therapies have seen amazing success in treating hematological cancers — will autoimmune diseases yield next?
This biotech is using the chromatin regulatory system to fight back against cancer
Foghorn Therapeutics recently announced dosing of the first patient in the Phase 1 trial of FHD-909 in collaboration with Eli Lilly.
Sarah Boyce's Avidity: A deep dive into one of the fastest growing biotechs of all time
Avidity Biosciences has achieved successful data readouts for all three of its programs in Phase 1/2 clinical trials, initiated its first Phase 3 trial, and raised over $1.1 billion this year.
How rationally designed therapeutics could revolutionize gene therapy
Gene therapy holds incredible promise, but the challenge has always been delivery - Affinia Therapeutics seeks to solve one of the most important problems that the industry faces.
New CEO Dr. Mike Exton has big plans for Lexicon Pharma in 2025
Lexicon has been discovering new genetic science since the Human Genome Project. Dr. Mike Exton, with over 2 decades of pharma experience, was drafted in this summer and has plans to make history.